An observational study in Sarcopenia and Diabetes Mellitus, sponsored by Fondazione Policlinico Universitario Agostino Gemelli IRCCS. Completed at 2 sites in Italy. Open to participants aged 70 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-04-19.
Sponsored by Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Observational
A thorough characterization of glucose metabolism and "inflammaging" in elderly subjects will help determine to what extent each of these factors affects muscle mass/function and contributes to age-related muscle wasting. The investigators will correlate patterns of insulin secretion/sensitivity with "muscle "quality/quantity" in diabetic and non-diabetic elderlies (≥70 years old). By comparing different groups (healthy, sarcopenic, diabetic, diabetic/sarcopenic), the investigators expect to identify an "oxidative/inflammatory signature" (e.g., circulating interleukins/myokines, plasma antioxidant capacity) specific for the sarcopenic phenotype and related to muscle insulin resistance.
1,206 studies on the registry are indexed under Sarcopenia; 401 are open to participants now.
This study's enrollment of 76 is below the median of 120 across 419 observational studies indexed under Sarcopenia.
Browse Sarcopenia studies →Fondazione Policlinico Universitario Agostino Gemelli IRCCS is the lead sponsor of 920 studies on the registry; 529 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Elderly (≥ 70 years) subjects
Inclusion Criteria:
Exclusion Criteria (overall population):
Exclusion Criteria (diabetic population):
Healthy elderlies
Elderlies with type 2 diabetes
Elderlies with sarcopenia
Elderlies with both type 2 diabetes and sarcopenia
Inflammatory markers (TNF-α, interleukin-1, interleukin-2, interleukin-6, RANKL, Myostatin and GDF11)
The primary objective of the study is to detect differences in inflammatory markers in the four groups
Time frame: 2 years
This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fondazione Policlinico Universitario Agostino Gemelli IRCCS